drugset / Trial / NCT03128619
Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer
Phase 1
Terminated
10 enrolled
Jonsson Comprehensive Cancer Center
Bayer · collabTranslational Research in Oncology · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This phase I/II trial studies side effects and best dose of copanlisib when given together with letrozole and palbociclib and to see how well they work in treating hormone receptor positive HER2 negative stage I-IV breast cancer. Copanlisib and palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs, such as letrozole, may lessen the amount of estrogen made by the body. Giving copanlisib, letrozole, and palbociclib may work better in treating patients with breast cancer.
Timeline
- Start
- 2017-08-02
- Primary completion
- 2022-03-31
- Completion
- 2022-03-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Copanlisib | Small molecule | — | Intravenous |
| Subject | Letrozole | Other / unclassified | — | Oral |
| Subject | Palbociclib | Small molecule | — | Oral |